EIF3L

Eukaryotic translation initiation factor 3 subunit L · Q9Y262 · EIF3L on Sugi Atlas →

0 patent compounds predicted against EIF3L, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to EIF3L by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer PHASE1/PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Quantification of GADD34 Expression in RA nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Autophagy Bladder Cancer nanUNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib nanCOMPLETED
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique nanCOMPLETED
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment nanUNKNOWN
Genomic Landscape of Intramedullary Astrocytoma nanUNKNOWN
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
miRNA as a Growth Plate Marker After GH nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EIF3L binder may also engage these)

ProteinNameSimilarity
Q3ZCK1 1.000 Q3ZCK1 →
A5A6M4 1.000 A5A6M4 →
Q8QZY1 1.000 Q8QZY1 →
Q5F428 1.000 Q5F428 →
Q6P878 1.000 Q6P878 →
Q7T2A5 1.000 Q7T2A5 →
Q8AVJ0 1.000 Q8AVJ0 →
A7RWP6 0.979 A7RWP6 →
Q8C8N2 0.978 Q8C8N2 →
Q3B8M3 0.977 Q3B8M3 →
Q9LNU4 0.976 Q9LNU4 →
O49160 0.976 O49160 →
Q8N9R8 0.975 Q8N9R8 →
EIF3A Eukaryotic translation initiation factor 3 subunit A 0.975 landscape →
Q1JU68 0.974 Q1JU68 →
Q9XHM1 0.974 Q9XHM1 →
Q6P7L9 0.974 Q6P7L9 →
Q8BWQ6 0.973 Q8BWQ6 →
Q5XI83 0.973 Q5XI83 →
Q6DRI1 0.972 Q6DRI1 →
P23116 0.972 P23116 →
B5DGH9 0.972 B5DGH9 →
Q9LQR8 0.972 Q9LQR8 →
Q5ZLA5 0.972 Q5ZLA5 →
Q9CRD2 0.971 Q9CRD2 →
Q05AY2 0.971 Q05AY2 →
Q5R882 0.971 Q5R882 →
Q6PCR7 0.971 Q6PCR7 →
P93768 0.971 P93768 →
Q5E993 0.970 Q5E993 →